| 来源类型 | Book |
| 规范类型 | 其他 |
| Pharmaceutical Price Regulation: Public Perceptions, Economic Realities, and Empirical Evidence | |
| John A. Vernon; Joseph H. Golec | |
| 发表日期 | 2009-01-30 |
| 出版者 | AEI Press |
| 出版年 | 2009 |
| 语种 | 英语 |
| 摘要 | Read the full PDF. Buy the book. Breakthrough drugs have saved millions of lives and improved the health of countless people around the world. Unfortunately, they are also expensive, leading many political leaders to call for price controls, importation, or other procedures to reduce their cost. In “Pharmaceutical Price Regulation: Public Perceptions, Economic Realities, and Empirical Evidence,” John A. Vernon and Joseph H. Golec argue that price controls and other cost-limiting measures will starve pharmaceutical companies of the R&D money required to develop new drugs. A drug can cost $1 billion or more before it ever appears in the marketplace — and only three out of every ten new drugs ever recoup their development costs. This groundbreaking monograph demonstrates empirically how the free-market system of drug pricing is vital to the development of new breakthrough drugs. Drug companies take a long-term view toward R&D investment, balancing projected profits against the costs of clinical development. This puts them in conflict with politicians, who tend to focus on the short-term concerns of current voters. Prices set in the political arena will reflect current voters’ wishes, as opposed to the full economic value of the pharmaceuticals. With less money to invest in R&D, drug companies would have no choice but to curtail product development that would serve the interests of future generations. While the United States has largely avoided the heavy-handed role of government price controls until now, Congress members and influential policymakers are setting the country on precisely this course. “Pharmaceutical price controls,” Vernon and Golec argue, “constitute a short-sighted, wrong-headed, and possibly dangerous policy. The prices set by the free market are the signals absolutely necessary for corporations to decide whether to undertake expensive, risky research into new drugs.” John A. Vernon is a professor in the Department of Health Policy and Management at the University of North Carolina at Chapel Hill, where he also holds appointments at the Kenan-Flagler Business School and the School of Pharmacy. He is a faculty research fellow with the National Bureau of Economic Research. Joseph H. Golec is an associate professor in the Department of Finance at the University of Connecticut. |
| 主题 | Health Care |
| 标签 | AEI Press ; drugs ; Health care policy ; medicine ; Pharmaceuticals ; prices ; Regulation |
| URL | https://www.aei.org/research-products/book/pharmaceutical-price-regulation-2/ |
| 来源智库 | American Enterprise Institute (United States) |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/208823 |
| 推荐引用方式 GB/T 7714 | John A. Vernon,Joseph H. Golec. Pharmaceutical Price Regulation: Public Perceptions, Economic Realities, and Empirical Evidence. 2009. |
| 条目包含的文件 | 条目无相关文件。 | |||||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
